Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway

Molecular Nutrition and Food Research

Volumn 59, Issue 11, 2015, Pages 2143-2154

  Trung, Ly Quoc ^a   Espinoza, J Luis ^a   An, Dao T ^a   Viet, Nguyen Hoang ^a   Shimoda, Kazuya ^b   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Apoptosis; JAK2 mutation; Resveratrol

Indexed keywords

ANTINEOPLASTIC AGENT; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PYRAZOLE DERIVATIVE; RESVERATROL; RUXOLITINIB; STAT PROTEIN; STILBENE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN; MUTATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASE 2; MUTATION; PYRAZOLES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; STILBENES;

EID: 84941786591     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201500166     Document Type: Article

References (42)

1. Levine, R. L., Pardanani, A., Tefferi, A., Gilliland, D. G., Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer 2007, 7, 673-683.
2. Khwaja, A., The role of Janus kinases in haemopoiesis and haematological malignancy. Br. J. Haematol. 2006, 134, 366-384.
3. Vainchenker, W., Dusa, A., Constantinescu, S. N., JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Seminars Cell Dev. Biol. 2008, 19, 385-393.
4. Silvennoinen, O., Hubbard, S. R., Molecular insights into regulation of JAK2 in myeloproliferative neoplasms. Blood 2015, 125, 3388-3392.
5. Rosenthal, A., Mesa, R. A., Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. Exp. Opin. Pharmacother. 2014, 15, 1265-1276.
6. Treliński, J., Robak, T., JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms. Curr. Med. Chem. 2013, 20, 1147-1161.
7. Bhagwat, N., Levine, R. L., Koppikar, P., Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms. Int. J. Hematol. 2013, 97, 695-702.
8. Koppikar, P., Bhagwat, N., Kilpivaara, O., Manshouri, T. et al., Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012, 489, 155-159.
9. Donnez, D., Jeandet, P., Clément, C., Courot, E., Bioproduction of resveratrol and stilbene derivatives by plant cells and microorganisms. Trends Biotechnol. 2009, 27, 706-713.
10. Chachay, V. S., Kirkpatrick, C. M., Hickman, I. J., Ferguson, M. et al., Resveratrol-pills to replace a healthy diet? Br. J. Clin. Pharmacol. 2011, 72, 27-38.
11. Cottart, C. H., Nivet-Antoine, V., Beaudeux, J. L., Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol. Nutr. Food Res. 2014, 58, 7-21.
12. Chen, L., Yang, S., Zumbrun, E. E., Guan, H. et al., Resveratrol attenuates lipopolysaccharide-induced acute kidney injury by suppressing inflammation driven by macrophages. Mol. Nutr. Food Res. 2015, 59, 853-864.
13. Espinoza, J. L., Takami, A., Trung, L. Q., Kato, S., Nakao, S., Resveratrol prevents EBV transformation and inhibits the outgrowth of EBV-immortalized human B cells. PloS One 2012, 7, e51306.
14. Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A. et al., Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010, 70, 9003-9011.
15. Shakibaei, M., Harikumar, K. B., Aggarwal, B. B., Resveratrol addiction: to die or not to die. Mol. Nutr. Food Res. 2009, 53, 115-128.
16. Patel, K. R., Scott, E., Brown, V. A., Gescher, A. J. et al., Clinical trials of resveratrol. Ann. NY Acad. Sci. 2011, 1215, 161-169.
17. Cottart, C. H., Nivet-Antoine, V., Laguillier-Morizot, C., Beaudeux, J. L., Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 2010, 54, 7-16.
18. Brisdelli, F., D'Andrea, G., Bozzi, A., Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr. Drug Metab. 2009, 10, 530-546.
19. Quoc Trung, L., Espinoza, J. L., Takami, A., Nakao, S., Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition. PLoS One 2013, 8, e55183.
20. Chou, T.-C., Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70, 440-446.
21. Podhorecka, M., Halicka, D., Klimek, P., Kowal, M. et al., Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia. Annal. Hematol. 2011, 90, 173-183.
22. Jones, A. V., Kreil, S., Zoi, K., Waghorn, K. et al., Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106, 2162-2168.
23. Luis Espinoza, J., Takami, A., Trung, L. Q., Nakao, S., Ataxia-telangiectasia mutated kinase-mediated upregulation of NKG2D ligands on leukemia cells by resveratrol results in enhanced natural killer cell susceptibility. Cancer Sci. 2013, 104, 657-662.
24. Yang, Q., Wang, B., Zang, W., Wang, X. et al., Resveratrol inhibits the growth of gastric cancer by inducing G1 phase arrest and senescence in a Sirt1-dependent manner. PloS One 2013, 8, e70627.
25. Nakaya, Y., Shide, K., Niwa, T., Homan, J. et al., Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J. 2011, 1, e29.
26. Quintas-Cardama, A., Vaddi, K., Liu, P., Manshouri, T. et al., Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115, 3109-3117.
27. Geissler, K., Ohler, L., Födinger, M., Kabrna, E. et al., Interleukin-10 inhibits erythropoietin-independent growth of erythroid bursts in patients with polycythemia vera. Blood 1998, 92, 1967-1972.
28. Kovanen, P. E., Junttila, I., Takaluoma, K., Saharinen, P. et al., Regulation of Jak2 tyrosine kinase by protein kinase C during macrophage differentiation of IL-3-dependent myeloid progenitor cells. Blood 2000, 95, 1626-1632.
29. Li, M. Y., Tian, Y., Shen, L., Buettner, R. et al., 3-O-methylthespesilactam, a new small-molecule anticancer pan-JAK inhibitor against A2058 human melanoma cells. Biochem. Pharmacol. 2013, 86, 1411-1418.
30. Muller, S., Chen, Y., Ginter, T., Schafer, C. et al., SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells. Oncotarget 2014, 5, 3184-3196.
31. Rubert, J., Qian, Z., Andraos, R., Guthy, D. A., Radimerski, T., Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival. BMC Cancer 2011, 11, 24.
32. Yu, L. J., Wu, M. L., Li, H., Chen, X. Y. et al., Inhibition of STAT3 expression and signaling in resveratrol-differentiated medulloblastoma cells. Neoplasia 2008, 10, 736-744.
33. Nakatake, M., Monte-Mor, B., Debili, N., Casadevall, N. et al., JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene 2012, 31, 1323-1333.
34. Qian, C., Yao, J., Wang, J., Wang, L. et al., ERK1/2 inhibition enhances apoptosis induced by JAK2 silencing in human gastric cancer SGC7901 cells. Mol. Cell. Biochem. 2014, 387, 159-170.
35. Nguyen, T. H., Mustafa, F. B., Pervaiz, S., Ng, F. S., Lim, L. H., ERK1/2 activation is required for resveratrol-induced apoptosis in MDA-MB-231 cells. Int. J. Oncol. 2008, 33, 81-92.
36. Banerjee Mustafi, S., Chakraborty, P. K., Raha, S., Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70. PloS One 2010, 5, e8719.
37. Walz, C., Crowley, B. J., Hudon, H. E., Gramlich, J. L. et al., Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J. Biol. Chem. 2006, 281, 18177-18183.
38. Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C. et al., Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest. New Drugs 2014, 32, 825-837.
39. Scott, E., Steward, W. P., Gescher, A. J., Brown, K., Resveratrol in human cancer chemoprevention-choosing the 'right' dose. Mol. Nutr. Food Res. 2012, 56, 7-13.
40. Howells, L. M., Berry, D. P., Elliott, P. J., Jacobson, E. W. et al., Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. (Phila) 2011, 4, 1419-1425.
41. Summerlin, N., Soo, E., Thakur, S., Qu, Z. et al., Resveratrol nanoformulations: challenges and opportunities. Int. J. Pharm. 2015, 479, 282-290.
42. Johnson, J. J., Nihal, M., Siddiqui, I. A., Scarlett, C. O. et al., Enhancing the bioavailability of resveratrol by combining it with piperine. Mol. Nutr. Food Res. 2011, 55, 1169-1176.